Details for New Drug Application (NDA): 021721
✉ Email this page to a colleague
The generic ingredient in LEVAQUIN is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.
Summary for 021721
| Tradename: | LEVAQUIN |
| Applicant: | Janssen Pharms |
| Ingredient: | levofloxacin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021721
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;ORAL | Strength | 250MG/10ML | ||||
| Approval Date: | Oct 21, 2004 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 021721
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Pharms | LEVAQUIN | levofloxacin | SOLUTION;ORAL | 021721-001 | Oct 21, 2004 | 5,053,407*PED | ⤷ Get Started Free |
| Janssen Pharms | LEVAQUIN | levofloxacin | SOLUTION;ORAL | 021721-001 | Oct 21, 2004 | 6,806,256*PED | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
